Slide 1: IR Presentation March 2025
IR PRESENTATION March 2025 ALL ON THE RADAR
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Forward-looking statements involve risks. This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realis
Slide 3: STRATEC at a Glance
STRATEC AT A GLANCE Leading OEM player for automation solutions for the diagnostics industry and translational research Three decades of experience in highly regulated healthcare markets and growing technology pool Around 1.500 employees worldwide Around 50% allocable to R&D Production sit
Slide 4: Corporate Social Responsibility
CORPORATE SOCIAL RESPONSIBILITY QUALITY ENVIRONMENTAL SOCIAL MANAGEMENT RESPONSIBILITY RESPONSIBILITY Highest quality standards Combat climate change Secure diverse and Established high-performance, Greenhouse gas reduction target1 inclusive work certified quality management in-line with Paris a
Slide 5: Unique Position Within the Value Chain
UNIQUE POSITION WITHIN THE VALUE CHAIN Shared responsibilities STRATEC provides instrumentation, consumables, software and automation solutions Analyzer Market OEM development and manufacturing Systems Access Partner Around 10,000 fully automated analyzer systems manufactured annually Wide ran
Slide 6: Active in Fast Growing Segments
ACTIVE IN FAST GROWING SEGMENTS IVD MARKET SEGMENTS / IVD MARKET: ~100 BILLION USD IVD market by technologies Focus on market segments with above average complexity and growth Molecular Diagnostics Random access analyser systems (mid-to-high throughput) Smart consumables (multiplexing) POC dev
Slide 7: Benefitting from Outsourcing Trend
BENEFITTING FROM OUTSOURCING TREND OUTSOURCED VS IN HOUSE INSTRUMENTATION MARKET The majority of instrumentation Trend of outsourcing towards specialized players set to continue, due to: equipment in the IVD market is still developed in-house by diagnostics Engineering of automation solutions ofte
Slide 8: Strong Recurring Revenue Base
STRONG RECURRING REVENUE BASE Smart consumables Service and spare parts Service parts and consumables (37% of sales) Maintenance parts Spare parts Classic plastic consumables (eg. Pipetting tips, reaction vessels) Perestaltic Pump Smart consumables (highly complex cartridges; microfluidics,
Slide 9: Strong Long-Term Customer Relationships
STRONG LONG-TERM CUSTOMER RELATIONSHIPS A SELECTION OF STRATEC CUSTOMERS Sales 2023 GLOBAL TOP 20 IVD COMPANIES (USD billion) 1. Roche 14.2 … And other technology pioneers 2. Abbott 10.0 3. Danaher 9.6 4. Siemens 4.8 5. Thermo Fisher 4.4 6. Becton Dickinson 3.6 7. bioMerieux 3.3 8. Sysmex 3.1 9. Qui
Slide 10: High-Sensitivity Immunoassays
MARKET – FOCUS AREAS HIGH-SENSITIVITY IMMUNOASSAYS EXPAND DOMINANT MARKET POSITION WITH INNOVATORS AND ESTABLISHED PLAYERS Focus Areas: • High-Multiplexing up to full proteome • Single Molecule Detection Technologies Proteomics Research Market: $2.0bn • High-Throughput rare-biomarker screening (Neur
Slide 11: Advanced Imaging
MARKET – FOCUS AREAS ADVANCED IMAGING DYNAMIC MARKET WITH EXPECTED PUSH BY AI Total addressable tools market – Advanced Imaging 1 Focus Areas: • Automation for digital imaging allowing for the combination of $bn CAGR traditional H&E stains with custom fluorescence labels 10 • Sample prep workflows a
Slide 12: Cell & Gene Therapy
MARKET – FOCUS AREAS CELL & GENE THERAPY FAST-GROWING MARKET WITH UNMET NEED FOR AUTOMATION Total addressable tools market – Cell Therapy Focus Areas: $bn • Cell Isolation (sorting and isolation of cell types of interest) CAGR • Transfection (genetic engineering of cells to create the therapy) 2 1.8
Slide 13: Key Figures - Track Record
FINANCIAL REVIEW KEY FIGURES - TRACK RECORD Sales CAGR ~7% Adjusted EBIT1 CAGR ~3% 60 350 54.3 300 287.3 50 274.6 45.1 261.9 41.7 250.0 250 40 36.4 207.5 214.2 32.3 200 184.9 187.8 29.3 30 26.9 26.2 27.1 144.9 146.9 24.1 150 128 19.5 20 100 10 50 0 0 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Slide 14: 9M 2024 at a Glance
FINANCIAL REVIEW 9M 2024 AT A GLANCE • Sales dynamics still affected by lower demand for MDx systems (COVID capacity built-up) and postponement of some deliveries to Q4 and FY 2025 • Efficiency measures and structural improvements unfolding momentum: Gross margin 9M/2024 up yoy despite lower economi
Slide 15: Financials at a Glance
FINANCIAL REVIEW FINANCIALS AT A GLANCE1 € 000s 9M/2024 9M/2023 Change Q3/2024 Q3/2023 Change -6.1% -8.7% Sales 176,305 187,680 57,229 62,674 (cc: -6,0%) (cc: -9,1%) Adjusted EBITDA 26,329 27,267 -3.4% 9,011 13,370 -32.6% Adjusted EBITDA margin (%) 14.9 14.5 +40 bps 15.7 21.3 -560 bps Adjusted EBIT
Slide 16: Sales Development 9M 2024
FINANCIAL REVIEW SALES DEVELOPMENT 9M 2024 Sales in € million 9M/2024 down by 6.0% yoy at constant currency to 250 € 176.3 million; -9.6% organic 225.4 207.7 (-) Lower pandemic-related demand for 200 187.7 molecular diagnostics solutions 179.1 176.3 158.3 (-) Flatter than expected ramp-up phase of 1
Slide 17: Adjusted EBIT and EBIT Margin 9M 2024
FINANCIAL REVIEW ADJUSTED EBIT AND EBIT MARGIN 9M 2024 Adj. EBIT in € million Adj. EBIT margin in % Adjusted EBIT margin 9M/2024 8.4% versus 8.6% 60 30% in the prior year period 55 28% 48.7 26% 50 24% (+) Efficiency measures and structural 45 22% 38.1 changes taking effect 40 20% 35 18% 28.1 16% 30
Slide 18: Cash Flow and Net Debt
FINANCIAL REVIEW CASH FLOW AND NET DEBT € 000s 9M/2024 9M/2023 Change • Significantly improved cash flow dynamics on Cash flow – operating activities 25,430 10,709 +137.5% the back of reduced trade receivables position and lower cash tax payments; but still inflated Cash flow – investment activities
Slide 19: Sales by Operating Divisions H1/2024
FINANCIAL REVIEW SALES BY OPERATING DIVISIONS H1/2024 Sales in € million In % of total sales -34.2% 100% 60 +17.7% (-34.4% at cc) (+17.5% at cc) 30.1% 50 80% 43.5% 40 +18.8% 60% (+18.9% at cc) 30 43.9% 54.4 52.3 40% 35.5% 44.4 20 35.8 30.4 25.5 20% 10 +5.0% 25.5% (+4.8% at cc) 20.4% 0.6 0.7 0 0% Sys
Slide 20: Financial Guidance for Fiscal Year 2024
OUTLOOK FINANCIAL GUIDANCE FOR FISCAL YEAR 2024 • Sales expected to remain stable or decline slightly compared with the previous year on a constant-currency basis • Adjusted EBIT margin of around 10.0% to 12.0% (2023: 10.3%) Sales and earnings dynamics are expected to improve significantly in the
Slide 21: Focus in 2025 and Beyond
OUTLOOK FOCUS IN 2025 AND BEYOND • Manage and process M&A opportunities according to external growth and diversification strategy • Maintaining cost discipline throughout the company given earnings improvement measures implemented • Continue to grow footprint in selected market focus areas • Execute
Slide 22: Appendix
f Stratecee APPENDIX 22 @—
Slide 23: Key Figures at a Glance
APPENDIX KEY FIGURES AT A GLANCE1 IFRS (€ million) 2019 2020 2021 2022 2023 Sales 214.2 250.1 287.3 274.6 261.9 Adjusted EBIT 29.3 41.7 54.3 45.1 27.1 Adjusted EBIT margin (%) 13.7 16.7 18.9 16.4 10.3 Adjusted Consolidated net income 24.1 35.2 45.1 34.7 16.7 Adjusted Earnings per share (€) 2.01 2.92
Slide 24: Adjustments 9M 2024
APPENDIX ADJUSTMENTS 9M 2024 EBIT Consolidated net income € 000s 9M/2024 9M/2023 € 000s 9M/2024 9M/2023 Adjusted EBIT 14,769 16,222 Adjusted consolidated net income 8,139 9,742 Adjustments: Adjusted earnings per share in € 0.67 0.80 (basic) PPA amortization -2,772 -1,713 Other1 -2,052 -1,217 Adjustm
Slide 25: Shareholder Structure
APPENDIX SHAREHOLDER STRUCTURE (AS OF: JANUARY 2025) Fixed and family ownership (incl. their investment companies) 40.3% Free float 59.7% Institutional investors > 3%: Brown Capital Management JPMorgan Chase & Co. Juno Investment Partners SHARE Union Investment Privatfonds IPO Aug. 1998 Number of sh
Slide 26: Thank You for Your Attention
CONTACT STRATEC SE THANK YOU Gewerbestr. 37 75217 Birkenfeld FOR YOUR Germany ATTENTION Phone +49 7082 7916-0 Fax +49 7082 7916-999 www.stratec.com CONTACT Jan Keppeler, CFA Head of Investor Relations, Sustainability & Corporate Communications Phone +49 7082 7916-6515 j.keppeler@stratec.com 26